TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Rehabilitation and Supported Employment for Severe Mental Illness
Brief Summary: The purpose of this study is help people with serious mental illness and receiving vocational rehabilitation get and keep the job they want by improving their thinking skills, such as attention and memory, using computer exercises and other strategies. One half of the participants in the study will receive vocational rehabilitation and the exercises to improve thinking skills, and the other half will receive just vocational rehabilitation. All participants will receive an assessment of symptoms and thinking skills at the beginning of the study and 6, 12, and 24 months later. Work activity during the 24 months in the study will be collected. It is expected that those participants who receive the practice of their thinking skills will be more likely to get and keep the job they want compared with people who do not receive this treatment.


Options:
A: Arm Label: Individual Placement and Support (IPS); Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and support (IPS) | Arm Label: IPS plus; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and support (IPS), Behavioral: IPS plus | Arm Label: Standard intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Individual Placement and support (IPS); Assigned to Arm(s): IPS plus, Individual Placement and Support (IPS) | Intervention Type: BEHAVIORAL; Name: IPS plus; Assigned to Arm(s): IPS plus
B: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes
C: Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Training | Arm Label: Standard Pharmacotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training
D: Arm Label: Supported Employment Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Employment | Arm Label: Thinking Skills for Work; Type: EXPERIMENTAL; Interventions: Behavioral: Thinking Skills for Work Program | Intervention Type: BEHAVIORAL; Name: Thinking Skills for Work Program; Assigned to Arm(s): Thinking Skills for Work | Intervention Type: BEHAVIORAL; Name: Supported Employment; Assigned to Arm(s): Supported Employment Only

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial.
Brief Summary: Long-standing diabetes is often complicated by retinopathy. The mechanisms that induce the development of diabetic retinopathy are incompletely understood and include alterations in bone marrow derived vasculogenic cells called "endothelial progenitor cells".

Fenofibrate is a PPAR-alpha agonist used for the treatment of mixed dislipidemia and hypertriglyceridemia. In a trial conducted in type 2 diabetic patients, the drug fenofibrate has reduced retinopathy-related endpoints suggesting a direct effect of the drug on the mechanisms that drive the development of this complication.

Herein, the investigators hypothesize that fenofibrate treatment can increase circulating EPC levels in diabetic patients with retinopathy, compared to placebo.


Options:
A: Arm Label: Dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal aflibercept injection [IAI] | Arm Label: Dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal aflibercept injection [IAI] | Arm Label: Dosing regimen 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham | Intervention Type: DRUG; Name: Intravitreal aflibercept injection [IAI]; Assigned to Arm(s): Dosing regimen 1, Dosing regimen 2 | Intervention Type: DRUG; Name: Sham; Assigned to Arm(s): Dosing regimen 3
B: Arm Label: Fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate 145 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fenofibrate 145 mg; Assigned to Arm(s): Fenofibrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Observation (Prompt Sham); Type: SHAM_COMPARATOR; Interventions: Procedure: Prompt Sham, Procedure: Deferred laser, Drug: Deferred aflibercept | Arm Label: Prompt aflibercept; Type: EXPERIMENTAL; Interventions: Drug: Prompt aflibercept, Procedure: Deferred laser, Drug: Deferred aflibercept | Intervention Type: PROCEDURE; Name: Prompt Sham; Assigned to Arm(s): Observation (Prompt Sham) | Intervention Type: DRUG; Name: Prompt aflibercept; Assigned to Arm(s): Prompt aflibercept | Intervention Type: PROCEDURE; Name: Deferred laser; Assigned to Arm(s): Observation (Prompt Sham), Prompt aflibercept | Intervention Type: DRUG; Name: Deferred aflibercept; Assigned to Arm(s): Observation (Prompt Sham), Prompt aflibercept
D: Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief Summary: The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma


Options:
A: Arm Label: Daromun plus Surgery and Adjuvant therapy (Arm 1); Type: EXPERIMENTAL; Interventions: Drug: Daromun, Procedure: Surgery, Drug: Adjuvant therapy | Arm Label: Surgery and adjuvant therapy (Arm 2); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: Adjuvant therapy | Intervention Type: DRUG; Name: Daromun; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1) | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1), Surgery and adjuvant therapy (Arm 2) | Intervention Type: DRUG; Name: Adjuvant therapy; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1), Surgery and adjuvant therapy (Arm 2)
B: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
C: Arm Label: Temozolomide (TMZ); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ) | Arm Label: Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI); Type: EXPERIMENTAL; Interventions: Drug: Temozolomide (TMZ), Drug: Pegylated Interferon Alpha-2b (PGI) | Intervention Type: DRUG; Name: Temozolomide (TMZ); Assigned to Arm(s): Temozolomide (TMZ), Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI) | Intervention Type: DRUG; Name: Pegylated Interferon Alpha-2b (PGI); Assigned to Arm(s): Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)
D: Arm Label: Surgery; Type: OTHER; Interventions: Procedure: Immediate surgical resection of melanoma lesion(s) | Arm Label: Talimogene Laherparepvec; Type: EXPERIMENTAL; Interventions: Drug: Talimogene Laherparepvec | Intervention Type: DRUG; Name: Talimogene Laherparepvec; Assigned to Arm(s): Talimogene Laherparepvec | Intervention Type: PROCEDURE; Name: Immediate surgical resection of melanoma lesion(s); Assigned to Arm(s): Surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief Summary: The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma


Options:
A: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
B: Arm Label: Cisplatinum + conventional RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatinum, Radiation: Conventional radiotherapy | Arm Label: Cisplatinum + adaptive high dose RT; Type: EXPERIMENTAL; Interventions: Drug: cisplatinum, Radiation: Adaptive radiotherapy | Intervention Type: DRUG; Name: cisplatinum; Assigned to Arm(s): Cisplatinum + adaptive high dose RT, Cisplatinum + conventional RT | Intervention Type: RADIATION; Name: Conventional radiotherapy; Assigned to Arm(s): Cisplatinum + conventional RT | Intervention Type: RADIATION; Name: Adaptive radiotherapy; Assigned to Arm(s): Cisplatinum + adaptive high dose RT
C: Arm Label: Panitumumab Plus Chemoradiation; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy, Drug: Panitumumab | Arm Label: Chemoradiotherapy Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: RADIATION; Name: Standard Fractionation Radiotherapy; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus Chemoradiation
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief Summary: The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma


Options:
A: Arm Label: Completion Lymphadenectomy; Type: EXPERIMENTAL; Interventions: Procedure: Completion Lymphadenectomy | Arm Label: Clinical Monitoring (Palpation and node ultrasound); Type: EXPERIMENTAL; Interventions: Procedure: Clinical Monitoring (Palpation and node ultrasound) | Intervention Type: PROCEDURE; Name: Completion Lymphadenectomy; Assigned to Arm(s): Completion Lymphadenectomy | Intervention Type: PROCEDURE; Name: Clinical Monitoring (Palpation and node ultrasound); Assigned to Arm(s): Clinical Monitoring (Palpation and node ultrasound)
B: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
D: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Brief Summary: The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
B: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
C: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
D: Arm Label: Nevi from participants; Type: EXPERIMENTAL; Interventions: Genetic: To test the frequency of BRAF and NRAS mutations among nevi | Intervention Type: GENETIC; Name: To test the frequency of BRAF and NRAS mutations among nevi; Assigned to Arm(s): Nevi from participants

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Brief Summary: The study compares the therapies of instant multivessel balloon angioplasty plus stent implantation or the balloon angioplasty plus stent implantation of the infarct artery alone with any possible graduated later treatment of the other vessels in patients with acute myocardial infarction with cardioganic shock.

The main study hypothesis is to explore if culprit vessel only PCI with potentially subsequent staged revascularization in comparison to immediate multivessel revascularization by PCI in patients with cardiogenic shock complicating acute myocardial infarction reduces the incidence of 30- day mortality and/or severe renal failure requiring renal replacement therapy.


Options:
A: Arm Label: Immediate multivessel PCI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate multivessel PCI | Arm Label: Culprit lesion only PCI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Culprit Lesion only PCI | Intervention Type: PROCEDURE; Name: Immediate multivessel PCI; Assigned to Arm(s): Immediate multivessel PCI | Intervention Type: PROCEDURE; Name: Culprit Lesion only PCI; Assigned to Arm(s): Culprit lesion only PCI
B: Arm Label: CCPR protocol; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECPR protocol; Type: EXPERIMENTAL; Interventions: Procedure: Extracorporeal cardiopulmonary resuscitation (ECPR) | Intervention Type: PROCEDURE; Name: Extracorporeal cardiopulmonary resuscitation (ECPR); Assigned to Arm(s): ECPR protocol
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: HeartNet Ventricular Support System | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical/Device Therapy | Intervention Type: DEVICE; Name: HeartNet Ventricular Support System; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Optimal Medical/Device Therapy; Assigned to Arm(s): Control
D: Arm Label: Extra-Corporal Life Support (ECLS); Type: ACTIVE_COMPARATOR; Interventions: Device: Extra-Corporal Life Support (ECLS) | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Extra-Corporal Life Support (ECLS); Assigned to Arm(s): Extra-Corporal Life Support (ECLS)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
Brief Summary: The overall aim of this project is to evaluate the effect of progressive nicotine reduction in cigarettes on smoking behavior, toxin exposure and psychiatric symptoms in smokers with comorbid mood and/or anxiety disorders.

Smokers with mood and/or anxiety disorder will smoke research cigarettes that will contain either a) nicotine content similar to their preferred usual brand of cigarettes, or b) nicotine content per cigarette that is progressively reduced from approximately 11.6 mg to 0.2 mg per cigarette over 18 weeks.

It is our hypothesis that nicotine intake will decline as a function of cigarette nicotine content in the Reduced Nicotine Content group without significant increases in tobacco smoke exposure, severity of nicotine withdrawal symptoms, mood and anxiety symptomatology or protocol non-adherence over time in the Reduced Nicotine Content group as compared with the control group.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: Reduced Nicotine Content Cigarettes; Type: EXPERIMENTAL; Interventions: Drug: Reduced Nicotine Content Cigarettes | Arm Label: Usual Nicotine Content Cigarettes; Type: PLACEBO_COMPARATOR; Interventions: Drug: Usual Nicotine Content Cigarettes | Intervention Type: DRUG; Name: Reduced Nicotine Content Cigarettes; Assigned to Arm(s): Reduced Nicotine Content Cigarettes | Intervention Type: DRUG; Name: Usual Nicotine Content Cigarettes; Assigned to Arm(s): Usual Nicotine Content Cigarettes
C: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
D: Arm Label: Placebo (Slow Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Slow Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Arm Label: Placebo (Normal Metabolizers); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine (Normal Metabolizers); Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal Nicotine | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline (Normal Metabolizers), Varenicline (Slow Metabolizers) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Normal Metabolizers), Placebo (Slow Metabolizers) | Intervention Type: DRUG; Name: Transdermal Nicotine; Assigned to Arm(s): Transdermal Nicotine (Normal Metabolizers), Transdermal Nicotine (Slow Metabolizers)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Brief Summary: The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
B: Arm Label: lebrikizumab - highest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - lowest dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: lebrikizumab - middle dose; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - highest dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - middle dose | Intervention Type: DRUG; Name: lebrikizumab; Assigned to Arm(s): lebrikizumab - lowest dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C